References
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2 + subtypes. Ann Surg Oncol. 2018;25(8):2241–8.
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.
Davis J, Boughey JC. Performance and clinical utility of models predicting eradication of nodal disease in patients with clinically node negative breast cancer treated with neoadjuvant chemotherapy by tumor biology. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08885-w.
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.
Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999;177(3):184–7; Discussion 188.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors report no disclosures.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Davis, J., Boughey, J.C. ASO Author Reflections: How Predictive Models Can Help Guide Axillary Surgery Decision Making After Neoadjuvant Chemotherapy. Ann Surg Oncol 27 (Suppl 3), 690–691 (2020). https://doi.org/10.1245/s10434-020-08933-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08933-5